| Enzyme-replacement therapy in life-threatening hypophosphatasia MP Whyte, CR Greenberg, NJ Salman, MB Bober, WH McAlister, ... New England Journal of Medicine 366 (10), 904-913, 2012 | 573 | 2012 |
| Prolonged survival and tissue trafficking following adoptive transfer of CD4ζ gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus … RT Mitsuyasu, PA Anton, SG Deeks, DT Scadden, E Connick, MT Downs, ... Blood, The Journal of the American Society of Hematology 96 (3), 785-793, 2000 | 515 | 2000 |
| Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study SA Nickel M, Simonati A, Jacoby D, Lezius S, Kilian D, Van de Graaf B ... Lancet Child & Adolescent Health 2 (8), 582-590, 2018 | 111 | 2018 |
| Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer CM Anderson, CM Lee, DP Saunders, A Curtis, N Dunlap, C Nangia, ... Journal of Clinical Oncology 37 (34), 3256-3265, 2019 | 101 | 2019 |
| WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind … A Ben Salah, PA Buffet, G Morizot, N Ben Massoud, A Zaˆatour, ... PLoS neglected tropical diseases 3 (5), e432, 2009 | 96 | 2009 |
| Some practical problems in implementing randomization M Downs, K Tucker, H Christ-Schmidt, J Wittes Clinical Trials, 235-245, 2010 | 30 | 2010 |
| Reports to Independent Data Monitoring Committees: An Appeal for Clarity, Completeness, and Comprehensibility KA Buhr, M Downs, J Rhorer, R Bechhofer, J Wittes Therapeutic innovation & regulatory science 52 (4), 459-468, 2018 | 17 | 2018 |
| Revisiting co-trimoxazole prophylaxis for African adults in the era of antiretroviral therapy: a randomized controlled clinical trial MB Laurens, RG Mungwira, N Nampota, OM Nyirenda, TH Divala, ... Clinical Infectious Diseases 73 (6), 1058-1065, 2021 | 13 | 2021 |
| Two-year tumor outcomes of a phase 2B, randomized, double-blind trial of avasopasem manganese (GC4419) versus placebo to reduce severe oral mucositis owing to concurrent … CM Anderson, CM Lee, D Saunders, AE Curtis, NE Dunlap, C Nangia, ... International Journal of Radiation Oncology* Biology* Physics 114 (3), 416-421, 2022 | 7 | 2022 |
| Outcome measures to assess efficacy of treatments for age-related macular degeneration J Wittes, M Downs Ophthalmology, S8-S14, 2009 | 7 | 2009 |
| Roman: Reduction in oral mucositis with avasopasem manganese (GC4419)—Phase 3 trial in patients receiving chemoradiotherapy for locally-advanced, non-metastatic head and neck … J Holmlund, JM Brill, CM Lee, D Saunders, ST Sonis, M Downs, ... Journal of Clinical Oncology 37 (15_suppl), TPS6096-TPS6096, 2019 | 3 | 2019 |
| 2-year outcomes of phase IIb, randomized, double-blind trial Of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and … CM Anderson, CM Lee, D Saunders, AE Curtis, N Dunlap, C Nangia, ... International Journal of Radiation Oncology, Biology, Physics 108 (3), e789, 2020 | 2 | 2020 |
| Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and … CM Anderson, CM Lee, D Saunders, AE Curtis, NE Dunlap, C Nangia, ... International Journal of Radiation Oncology, Biology, Physics 106 (5), 1221-1222, 2020 | 2 | 2020 |
| ROMAN: Reduction in oral mucositis with avasopasem manganese (GC4419)–Phase III trial in patients receiving chemoradiotherapy for locally advanced, nonmetastatic head and neck … J Holmlund, JM Brill, R Fairbanks, D Saunders, ST Sonis, M Downs, ... Journal of Clinical Oncology 38 (15_suppl), TPS6596-TPS6596, 2020 | 1 | 2020 |
| O62–1673 The natural history of late infantile CLN2 disease: striking homogeneity of clinical progression in two independently obtained large clinical cohorts A Schulz, M Nickel, M Downs, J Mezey, H Landy, D Sondhi, D Jacoby, ... European Journal of Paediatric Neurology, S20, 2013 | 1 | 2013 |
| Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV C Davis, D Singh, K Anderson, A Vardeu, J Kopycinski, A Bridges-Webb, ... Vaccines 12 (6), 644, 2024 | | 2024 |
| Reply to Ramirez and Diaz-Quijano MB Laurens, M Downs, MK Laufer Clinical Infectious Diseases 73 (8), 1551-1552, 2021 | | 2021 |
| The Natural History of Late Infantile CLN2 Disease: Striking Homogeneity of Clinical Progression in Two Independently Obtained Large Clinical Cohorts A Schulz, M Nickel, M Downs, J Mezey, H Landy, D Sondhi, D Jacoby, ... ANNALS OF NEUROLOGY 74, S131-S131, 2013 | | 2013 |
| A SAS® macro to generate enhanced Kaplan-Meier plots H Christ-Schmidt, M Downs Proceedings of Annual Conference of the SAS Users Group International, SUGI …, 2005 | | 2005 |
| Survival in an uncontrolled study of Motexafin Gadolinium compared to replicates of matched historical controls M Downs, M Renschler, J Wittes AMERICAN JOURNAL OF EPIDEMIOLOGY 157 (11), S54-S54, 2003 | | 2003 |
